US Stock Insider Trading | Mineralys disclosed 2 insider transactions on February 11

On February 11, 2026, Mineralys (MLYS) disclosed two insider trading transactions. Executive Rodman David Malcom purchased 2,171 shares on February 9, 2026.

【Recent Insider Transactions】

【Company Profile】

Mineralys Therapeutics, Inc., originally incorporated on May 31, 2019, is a Delaware-based company. It is a clinical-stage biopharmaceutical company focused on developing drugs to treat diseases caused by abnormally elevated aldosterone levels. The company’s lead candidate, Clorolone, is a proprietary oral highly selective aldosterone synthase inhibitor (ASI). It was initially developed to treat uncontrolled hypertension (uHTN), defined as individuals who, despite taking two or more antihypertensive medications or resistant hypertension (rHTN), still do not reach blood pressure below 130/80 mmHg. In the U.S., over 115 million patients suffer from persistent hypertension, with more than half failing to meet blood pressure targets, which are currently set at 130/80 mmHg with available medications. Over 30 million treated patients do not reach blood pressure goals, with about 20 million having systolic BP over 140 mmHg. Despite taking multiple medications, hypertensive patients remain at increased risk of cardiovascular disease or stroke, with mortality risks 1.8 and 2.5 times higher, respectively. In a Phase 2 clinical trial evaluating 200 subjects with uHTN and rHTN (target HTN), Clorolone administered once daily showed clinically and statistically significant blood pressure reductions and was well tolerated. Beyond hypertension, the company also plans to develop Clorolone for the treatment of chronic kidney disease (CKD).